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INTRODUCTION 
 
 Soft tissue sarcomas are rare tumors comprising less than 1% of all malignant 
tumors whereas extremity soft tissue sarcomas (ESTS) make up about 60% of soft 
tissue sarcomas [1,2]. The treatment of ESTS has changed since the 1980s from 
radical amputations to limb sparing surgery in combination with adjuvant 
radiotherapy with very similar results, which has been addressed by a prospective, 
randomized trial at the NCI [3]. Limb sparing excisions can be achieved in 
approximately 95% of patients. Adjuvant radiotherapy enhances local control, 
preserve function, and achieve acceptable cosmesis by contributing to tissue 
preservation.  Because upto half of patients with sarcomas after adequate local 
control of the disease will develop distant metastasis, usually to the lungs. It was 
hoped that adjuvant chemotherapy would help to decrease the frequency of distant 
metastasis and increase overall survival. In meta-analysis regarding adjuvant 
chemotherapy was shown an absolute overall survival of 7% in the group receiving 
chemotherapy for extremity sarcomas. There are various controversial issues 
concerning the management of ESTS after unplanned resection such as patient 
selection for re-excision, imaging before re-excision, factors affecting local and 
distant recurrence, and the choice of adjuvant therapies. 
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REVIEW OF LITERATURE 
EPIDEMIOLOGY 
 
 Sarcoma is a rare malignant tumor that represents a significant challenge to 
oncologists due to the large number of distinct histologies, each with its own natural 
history. They represent less than 1% of all malignancies in adults. They may arise in 
any anatomic site, although for convenience they are typically categorized into the 
extremity, trunk, head & neck, retroperitoneal and visceral sites [4]. STS are slightly 
more common in males than in females, in a ratio of 1.4:1. There are more than 50 
subtypes of STS. According to the American Cancer Society, the most common 
types are malignant fibrous histiocytoma (28%), liposarcoma (15%), 
leiomyosarcoma (12%), synovial sarcoma (10%), malignant peripheral nerve sheath 
tumors (6%), and rhabdomyosarcoma (5%). All other types of STS occur in 
percentages of 3% or less [5]. 
 
 According to Madras Metropolitan Tumor Registry approximately the 
incidence of soft tissue sarcoma per lakh population are 1% in male and 0.9% in 
female. According to our Cancer Institute Registry, each year from 1996 to 2005, 
approximately 9000 to 12000 new cancer cases were registered in our institute. Soft 
tissue sarcomas accounts for 2% of male and 1 % of female cases of total number of 
new cases registered. This includes adult sarcomas like primary, unplanned 
excisions, recurrent, metastatic sarcomas and some benign tumor like schwannoma, 
fibromatosis and DFSP and pediatric sarcomas. Adult extremity soft tissue sarcomas 
accounts for 40 to 50% percent of all cases.  
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Etiology 
 
 As with other malignant neoplasms, the pathogenesis of most soft tissue 
sarcomas is still unknown, although multiple associated or predisposing factors have 
been identified. Evaluation of the exact cause is often difficult because of the long 
latent period between the time of exposure and the development of sarcoma, as well 
as the possible effect of multiple environmental and hereditary factors during the 
induction period. There are many risk factors related to the development of sarcomas 
like radiation exposure[6,7], viruses, environmental factors, chronic lymphedema [8], 
chemical carcinogens, immunosuppression and genetics factors [9, 10]. 
 
Pathology 
 
 Soft tissue sarcoma probably arises from pleuripotent mesenchymal stem cell. 
There are wide varieties of histological subtypes of sarcomas, and clinical behavior 
can be subtly or significantly different depending on histological type. There are 19 
histological categories and over 50 subtypes of STS described by Enzinger and 
Weiss [5]. Following table displays only the malignant tumors arising from the 
respective mesenchymal tissues according to WHO classification [11].  
 
Table-1: Histologic Classification of Soft Tissue Tumors 
FIBROUS TUMORS 
Fibrosarcoma 
 Adult fibrosarcoma, usual type 
SYNOVIAL TUMORS 
Malignant giant cell tumor of tendon 
sheath 
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 Low grade fibromyxoid sarcoma 
 Sclerosing epithelioid fibrosarcoma 
FIBROHISTIOCYTIC TUMORS 
Malignant Fibrous Histiocytoma(MFH) 
Follicular dendritic cell tumor/sarcoma 
Interdigitating reticular cell tumor 
True histiocytic sarcoma 
Inflammatory myofibroblastic tumor 
LIPOMATOUS TUMORS 
Liposarcoma 
 Well-differentiated liposarcoma 
 Dedifferentiated liposarcoma 
 Myxoid-round cell liposarcoma 
 Pleomorphic liposarcoma 
SMOOTH MUSCLE TUMORS 
Leiomyosarcoma 
SKELETAL MUSCLE TUMORS 
Rhabdomyosarcoma 
 Alveolar rhabdomyosarcoma 
 Embryonal rhabdomyosarcoma 
 Botryoid rhabdomyosarcoma 
 Pleomorphic rhabdomyosarcoma 
 Rhabdomyosarcoma with ganglionic 
NEURAL TUMORS 
Malignant peripheral nerve sheath 
tumor (MPNST)(neurofibrosarcoma) 
Malignant granular cell tumor 
Primitive neuroectodermal tumors 
Neuroblastoma 
Ganglioneuroblastoma 
PARAGANGLIONIC TUMORS 
Malignant paraganglioma 
EXTRASKELETAL 
CARTILAGINOUS AND OSSEOUS 
TUMORS 
Extraskeletal chondrosarcomas 
Extraskeletal myxoid 
chondrosarcoma 
Mesenchymal chondrosarcoma 
Extraskeletal osteosarcoma 
PLURIPOTENTIAL 
MESENCHYMAL TUMORS 
Malignant mesenchymoma 
MISCELLANEOUS TUMORS 
Alveolar soft part sarcoma 
Epithelioid sarcoma 
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differentiation(ectomesenchymoma) 
TUMORS OF BLOOD AND LYMPHATIC 
VESSELS 
Epithelioid hemangioendothelioma 
Angiosarcoma and lymphangiosarcoma 
Kaposi sarcoma 
PERIVASCULAR TUMORS 
Malignant glomus tumor 
(glomangiosarcoma) 
Malignant hemangiopericytoma / solitary 
fibrous tumor 
Malignant extrarenal rhabdoid tumor 
Desmoplastic small round cell tumor 
Extraskeletal Ewing sarcoma 
Clear cell sarcoma (melanoma of soft 
parts) 
Synovial sarcoma 
UNCLASSIFIED TUMORS 
 
Clinical features 
 
 Soft tissue sarcomas most commonly present as a painless swelling. The size 
at presentation usually depends on the location of the tumor. Tumors in the distal 
extremities are often small when discovered, whereas tumors in the proximal 
extremities are usually large and deep seated. Soft tissue sarcomas grow in a 
centrifugal fashion and compress surrounding normal structures, but rarely does 
impingement on bone or neurovascular bundles produce pain, edema, and swelling. 
Presence of pain is usually associated with large deep seated tumor or with 
hemorrhage or necrosis or involvement nerves or bone. In neglected cases tumor may 
ulcerate. Lung is the commonest site for distant metastasis, rarely to bone, liver and 
brain. Usually symptoms of lung metastasis are cough with hemoptysis or dyspnea.  
Bone pain and central nerves system symptoms usually seen in recurrent tumors. 
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Evaluation  
 
 Patients should be thoroughly evaluated with detailed history, examination, 
review of slides and paraffin blocks and surgical notes obtained from patients who 
have been treated initially elsewhere. MRI/ CT scan of local part should be done 
before doing biopsy. Biopsy of tumor aids in histopathological examination and 
ancillary test like immunohistochemistry, electron microscopy and genetic study. 
Local imaging with MRI or CT scan of tumor bed is done in unplanned excision. 
Metastatic workup includes chest x-ray and CT scan of thorax.  
 
Biopsy:  
 
 The principal reasons for securing a preoperative tissue diagnosis in 
suspected soft tissue sarcoma are to distinguish these tumors from benign soft tissue 
tumors or metastatic carcinoma, and also to identify chemosensitive tumors such as 
primitive neuroectodermal tumours/ Ewing's sarcomas. Tissue for histological 
diagnosis can be obtained either by trucut biopsy, incision or excisional biopsy. 
Before biopsy local imaging should be considered where ever there is clinical 
suspicion of sarcoma because characterizing the lesion before distortion is better than 
that may accompany the biopsy. Adequate sample of tissue is necessary for definitive 
histology, grade and to identify prognostic factors that would alter the approach to 
definitive treatment. Biopsy helps plan multidisciplinary treatment and mandatory 
when neoadjuvant treatment is planned. Tissue obtained are subjected for 
 7
histopathological evaluation, immunohistochemistry, and, when necessary, electron 
microscopy and molecular markers [12]. 
 
a) Trucut biopsy: 
 
 Trucut biopsy is done using a 16 to 18F core needle. Biopsy should be done 
along the line future incision and nearest track to the skin and the tumor without 
contaminating the compartment. Adequate specimen should be taken and confirm 
adequacy if frozen section is available.  
 
b) Incisional biopsies:  
 
 Play an important role in evaluation of soft tissue tumor, where decisions’ 
regarding tissue diagnosis is doubtful. It is usually done when repeated trucut biopsy 
have failed. The major concern is tumor seeding and loss of tissue plane. To reduce 
the risk of seeding, the general guidelines of incisional biopsy should be followed: 
 
1. Incisions oriented along the long axis of the extremity and along the line of 
the future incision. 
2. The incision should be placed directly over the most superficial part of the 
tumor whenever possible, allowing a surgical approach that avoids crossing 
through uninvolved compartments to minimize contamination of normal 
tissues [13].  
3. Should not elevate the flaps. 
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4. Complete hemostasis to avoid hematoma and wound complications [14]. 
Meticulous hemostasis to avoid hematoma and possible contamination of 
adjacent muscle compartments. 
5. Adequate tissue for histopathology and utilize frozen section to ensure 
adequate tissue for diagnosis has been obtained.  
6. Drain should be avoided if possible or else keep a drain close to incision so 
that can be excised along with scar. 
7. Excision of the biopsy scar and tract is required if a sarcoma is diagnosed. 
Poorly planned incisions may result in increased wound morbidity during 
resection and lose the chance of limb salvage [15].  
 
c) Fine-Needle Aspiration Cytology:  
 
 At present FNAC is confined to the confirmation of recurrence or rule out a 
metastatic focus. Even though FNAC material is sufficient to diagnose sarcoma, 
histological grading of tumor is not possible [16].  
 
d) Frozen Section 
 
 It is helpful to confirm the adequacy of tissue biopsy and for diagnosis of 
malignancy. Frozen section is accurate, but for histopathologic subtypes and grade, it 
is inferior to permanent sections.  It may help to confirm the margin status after 
resection. 
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Imaging of local part: 
 
 Pretreatment radiological imaging is critical for defining the local extent of a 
tumor, staging the disease, guiding biopsies, and aiding in diagnosis. Imaging studies 
are also crucial in monitoring tumor changes after treatment, especially after 
preoperative chemotherapy or radiation therapy, and in detecting recurrences after 
surgical resection. Each imaging modality, however, has a particular place in patients 
with soft tissue sarcomas. 
 
Magnetic Resonance Imaging / CT scan: 
 
 Contrast enhanced CT can assess the extent of the soft tissue tumor. It also 
provides detailed information with respect to adjacent organs and vascular structures. 
Magnetic resonance images are excellent at delineating tissue planes, neurovascular 
structures, and characterization of soft tissue tumors without the use of radiation. 
MRI is better to characterize benign and malignant soft tissue tumors accurately in a 
high percentage of cases [17, 18, 19]. Totty et al. compared MRI with CT scanning 
for evaluating soft tissue tumors of the extremities [17]. The T1-weighted MR 
images better delineated extension of tumors into surrounding fatty tissue and the 
T2-weighted and spin-density MR images were superior in detecting tumor extension 
into muscle. Overall, the MRI yields superior resolution images to CT scanning in 
33% of comparisons. The only deficiency they identified was the limited ability of 
MRI to demonstrate soft tissue calcification and gas. In a study comparing MRI with 
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CT in the evaluation of 27 extremity soft tissue tumors, Week’s and associates found 
that MRI was able to adequately assess neurovascular involvement in 80% of cases 
compared with 62% of CT scans [19]. Verstraete and colleagues utilized contrast-
enhanced techniques in MRI, demonstrating an improved ability to depict tissue 
vascularization and perfusion [18]. This advantage is relevant in biopsy planning, 
where the highest yield specimens are more likely to be obtained from viable, well-
perfused areas. When bony involvement or destruction is of concern, CT scanning is 
better suited than MRI. 
 
Metastatic workup 
 
 Sarcomas disseminate almost exclusively through the blood; lack a lymphatic 
system. Early lymphatic spread to regional nodes has only rarely been reported. Most 
common site of distant metastasis is lung for extremity sarcomas, 90% develop in 
lung. Although chest X-ray not as sensitive as other imaging techniques, the chest 
radiograph is still probably the most specific in the diagnosis of lung metastasis. As 
the most common surveillance tool, the chest radiograph is often the first indication 
of lung metastasis. CT scan chest is superior to x-ray in detecting lung metastasis 
[20] and it is mandatory for sarcomas according to NCCN guidelines. Ultrasound and 
bone scan are not necessary since chance of bone and liver metastasis in extremity 
sarcoma is very rare. Bone scan be considered only in symptomatic or suspected 
cases.  
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Positron emission tomography   
 
 The role of positron emission tomography (PET) has not been clearly 
defined. It is primarily used in the identification of unsuspected sites of metastasis in 
patients with recurrent high-grade tumors. It appears that tumor grade may be 
distinguished. Specifically for primary extremity sarcomas, PET response correlated 
better with outcome than did radiologic tumor size changes after treatment with 
neoadjuvant chemotherapy [21]. Similar results have been found for pediatric 
sarcomas. It is used to evaluate patients with doubtful pulmonary metastasis. It is 
now well recognized that PET can be used to predict response to chemotherapy [22]. 
 
Grade of tumor:  
 
 After establishing the diagnosis of sarcoma, the most critical piece of 
information the pathologist can provide to the clinician is histological grade. 
Histological grade is the most important prognostic factor for adult soft tissue 
sarcoma. This has been shown in several multivariate studies and is clearly stated in 
the World Health Organization classification. The pathologic features that define 
grade include cellularity, histological type and subtype and/or differentiation, 
pleomorphism, necrosis, and number of mitoses. Unfortunately, the criteria for 
grading are neither specific nor standardized. Several grading scales and systems are 
used: a four-grade system (Broders) [23] a three-grade system (low, intermediate, 
high) such as the National Cancer Institute (NCI) grading system [24] and that of the 
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French Federation of Cancer Centers Sarcoma Group [25] and a binary system (high 
vs. low) as is used at MSKCC[26].Even when there is agreement about the number 
of grades to be used, expert pathologists disagree about specific criteria for defining 
grade. 
 
Staging  
 
 Classification based on 7th edition of International Union Against Cancer 
(UICC) on cancer staging. Staging includes grade of the tumor [27].  
 
DEFINITIONS 
Primary Tumor (T) 
 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Tumor 5cm or less in greatest dimension 
 T1a Superficial tumor 
 T1b Deep tumor  
T2 Tumor more than 5 cm in greatest dimension 
 T2a Superficial tumor 
 T2b Deep tumor 
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Regional Lymph Nodes (N)  
 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
 
Distant Metastasis (M) 
 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
Histologic Grade (G) 
 
GX Grade cannot be assessed 
G1 Well differentiated 
G2 Moderately differentiated 
G3 Poorly differentiated 
G4 Poorly differentiated or undifferentiated (four-tiered systems only)  
 
STAGE GROUPING 
 
IA  T1a  N0 NX M0 G1–2 G1 Low 
 T1b N0 NX  M0 G1–2 G1 Low 
IB  T2a  N0  NX  M0  G1–2  G1  Low 
 T2b  N0  NX  M0  G1–2  G1  Low 
IIA  T1a  N0  NX  M0  G3–4  G2–3  High 
 T1b  N0  NX  M0  G3–4  G2–3  High 
IIB  T2a  N0  NX  M0  G3–4  G2–3  High 
III  T2b  N0 NX  M0  G3–4  G2–3  High 
  Any T  N1  M0  Any G  Any G  High or Low 
IV Any T  Any N M1  Any G  Any G High or Low 
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Management 
 
 Surgery: The most effective single-modality treatment for localized soft 
tissue sarcoma is complete resection with aim to obtain a 1- to 2-cm margin of 
uninvolved tissue in all directions. Amputation should be reserved for tumors that 
cannot be resected by any other means, without evidence of metastatic disease and 
the potential for good long-term functional rehabilitation. This usually includes 
patients with large, low-grade tumors with considerable cosmetic and functional 
deformity, who can be rendered symptom free by a major amputation. Rosenberg 
and associates reported a prospective 2:1 randomized trial of 43 patients comparing 
limb-sparing surgery (wide excision) and postoperative radiation to amputation; all 
patients received postoperative systemic chemotherapy. They found that the local 
recurrence rate was marginally higher in the group undergoing limbsparing surgery 
(P = 0.06), but a large majority of patients in the limb-sparing surgery group had 
successful local control of their tumors. There was no statistical difference in overall 
survival between the two arms [3]. 
 
 The basic oncological process of growth and its relation to surgery is 
explained by Enneking’s. As sarcomas grow it compresses the normal tissue forms a 
pseudocapsule. At the periphery of the tumor immune reaction against the tumor 
cells forms the reactive zone. Through this capsule small finger like projection grows 
towards reactive zone. When these projections get separated from the main tumor 
and grow within and around the reactive zone leads to satellite nodules. When these 
nodule metastasis beyond 2cm from tumor in the same or different compartment it is 
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called as skip metastasis. There are 4 types of excision based on these oncological 
process explained by Enneking’s [28].  
 
1. Intracapsular resections are usually a result of “shell out” of an apparently 
encapsulated tumor when a malignant diagnosis was not anticipated.  
2. Marginal resection, the plane of dissection is outside the pseudocapsule but 
before or within the surrounding reactive zone.  
3. Wide resection consists of resection of surrounding normal tissue outside the 
reactive zone.  
4. Radical resection involves amputation of limb. 
 
Unplanned Excision 
 
 Surgeons working outside specialized oncology centers are expected to have 
less experience with soft tissue sarcoma. For this reason, sarcomas are frequently 
evaluated as benign soft tissue tumor and undergo unplanned excision.  In this 
situation, these masses are initially treated with a marginal excision with no regard to 
the surgical margins and without proper preoperative use of imaging modalities. 
 
 Giuliano and Eilber introduced the term ‘unplanned excision’ for this type of 
surgical approach to soft tissue sarcomas [29]. The treatment of these patients 
requires special attention. The status of surgical margins, histological diagnosis, and 
tumor grade should be re-evaluated at the specialist center before a re-excision is 
performed and accurate staging of the patient should be accomplished to decide on 
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treatment modalities. Either computerized tomography and/or magnetic resonance 
imaging should be used to visualize any possible residual tumor in the extremity. If 
macroscopic tumor cannot be detected by radiological examination and the surgical 
margins are negative, further treatment with adjuvant modalities should be planned 
depending on the tumor properties. However, the correlation between radiological 
findings and residual tumor is poor after unplanned resection due to the disruption of 
anatomical planes, and the role of magnetic resonance imaging in the assessment of 
residual tumors following unplanned resection is doubtful [30]. On the other hand, 
Manoso et al reported that 90% of patients with radiological evidence of tumor 
positivity had residual disease, whereas this rate was 25% for patients with no 
radiological evidence of tumor [31]. Re-excision after an unplanned resection is a 
difficult task for the surgeon. Since the gross tumor has been completely removed, 
the surgeon has neither visual nor tactile evidence of tumor extent. In addition, the 
surgeon cannot determine the exact extent of tissue dissection and the area of 
contamination by cancer cells during the primary operation due to the presence of 
dense scar tissue indistinguishable from tumor tissue, even by frozen section 
examination. As a result, unnecessarily wide surgical resections are performed after 
an unplanned resection that will cause deformity in the extremity. Most of these 
patients will require reconstruction after re-excision and the functional outcomes, 
especially of the upper extremity, may be suboptimal. 
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Residual tumor in re-excision specimens: 
 
 he extent of surgery during unplanned resection is vital since it will determine 
the amount of residual tumor tissue directly affecting the chance of local recurrence. 
However, the clinical significance of right width of surgical margins for resections 
with wide margins is controversial [28]. Previous studies have reported a residual 
tumor rate of 24% to 63% after unplanned resections [29, 32-34]. Soft tissue 
sarcomas are expected to have extensions into the surrounding tissues 
macroscopically undetectable during surgery. Hence, tumor spreading beyond the 
natural boundaries such as the fascial planes is highly probable during an unplanned 
resection. Re-excision removes the unappreciated residual tumor that extends beyond 
the pseudocapsule of the primary tumor and was performed in 24% to 100% of 
patients in previous studies [29, 32, 33, 35-37]. During re-excision, all skin and 
subcutaneous tissue overlying the contaminated wound as identified by imaging 
modalities should be removed. The presence of residual disease in re-excision 
specimens is reported to be a risk factor for local recurrence and has no effect on 
prognosis [35 to 37]. In addition, residual tumor has been detected less frequently 
after unplanned resections, if patients with macroscopic tumors were excluded [31, 
41]. High rates of residual tumor justify further surgery in order to decrease the rate 
of local recurrence.  The factors that determine for residual disease in re-excision 
specimens are not clear but patients with positive and uncertain margins after 
unplanned resection should definitely undergo re-excision. Re-excisions should be 
avoided when the boundaries of the contaminated surgical bed are unclear, when 
improvement in surgical margins is unlikely due to the proximity to vital structures 
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and/or neurovascular bundle, and when further surgery would lead to increased 
morbidity [42]. 
 
Local recurrence and survival: 
 
 tudies evaluating extremity STS patients identified a link between positive 
microscopic margins at initial resection and local recurrence [43-46]. However, the 
association between local recurrence and subsequent systemic metastases and tumor 
related death is less clear. There are studies stating that positive margin status or 
microscopic residual disease after re-excision may affect systemic metastases and 
survival [37, 38, 46, 47]. In this scenario, either local recurrence may contribute to 
the occurrence of distant metastases and poor patient survival, or an aggressive tumor 
may predispose to both local recurrence and distant metastases at the same time. 
Prognostic factors affecting local recurrence were reevaluated in patients with ESTS 
treated with an initial unplanned resection in previous studies. Local control is 
improved with repeated wide margin resections after incomplete primary surgery 
[35, 37, 39, 48]. On the other hand, local recurrence rate increases in patients initially 
treated with an unplanned resection outside the specialized centers compared to those 
primarily treated at specialized centers [49]. In contrast to this, local outcome is 
reported to be similar in patients treated at specialized centers with definitive 
resection or re-excision after unplanned resection [35, 37]. However, patient 
selection bias may have played a role as small, benign looking, and superficially 
located masses are usually treated with an unplanned resection outside the 
specialized centers whereas masses that are malignant in appearance are initially 
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referred to oncology centers. Previous studies have reported a 5-year survival rate of 
62% to 84% for patients treated at a referral center starting with a core needle or 
incisional biopsy followed by planned wide excisions and adjuvant therapies. 
Although tumor seeding along the anatomical planes can be controlled by 
postoperative radiotherapy, the possibility of distant metastases may increase 
resulting in a decrease in overall survival. For these reasons, re-excision after an 
unplanned resection decreases distant metastases and improves overall survival [35, 
37, 38]. The final margin status after re-excision is an independent predictor of 
disease-free and overall survival. Achieving negative surgical margins is the most 
effective factor to control distant spread and survival after an unplanned resection 
[37]. Re-excision after unplanned resection in the case of negative margins should be 
performed cautiously. In the study by Atalay et al [40], after an unplanned resection, 
patients were grouped as those with positive microscopic margins and those with 
negative microscopic margins treated with re-excision or without further surgical 
therapy. In multivariate analysis, low tumor grade and adjuvant radiotherapy were 
the independent prognostic factors prolonging disease-free survival, however, only 
re-excision without radiations in the case of negative margins decreased overall 
survival after unplanned resection [40]. An explanation for the difference in survival 
may be the selection or treatment biases. Since surgery is unavoidable, more radical 
surgery could have been performed for patients with positive surgical margins. Even 
if this was the case, survival was longer in patients with negative margins treated 
without further surgery compared to those with positive margins. 
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Adjuvant treatment  
Radiotherapy 
 
 he goals of adjuvant radiotherapy in the management of soft tissue sarcoma 
are to enhance local control, preserve function, and achieve acceptable cosmesis by 
contributing to tissue preservation. Adjuvant radiotherapy is indicated in tumor size 
more than 5cm of any grade, but the role of radiotherapy for high grade tumor less 
than 5cm is not defined. The benefit of adjuvant radiotherapy in enhancing local 
control with conservative surgical resection in soft tissue sarcoma overall has been 
demonstrated in two randomized clinical trials, one using EBRT and the other using 
Brachytherapy, with corroboration in a third trial with high local control that 
compared two EBRT strategies [50- 52].  
 
External Beam Radiation Therapy:  
 
 BRT is the most popular adjuvant radiotherapy approach, perhaps because 
there is less reliance on special technical and operational requirements than are 
needed for Brachytherapy, which include specific collaboration between surgical and 
radiation oncologists. EBRT requires comprehensive and multidisciplinary 
pretreatment consultation and accurate pathologic and radiologic assessment. 
Radiation can be given pre-operatively or post operatively. 
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 Rationale for Preoperative External-Beam Radiation Therapy: The 
hypothetical principle in pre-operative radiotherapy is that radiotherapy given with 
intact vascular supply and microenvironment with a relative absence of actively 
proliferating tumor clonogens and radioresistant hypoxic cells, which results in a 
need for lower doses in pre-operative radiotherapy. At a median of 3.3 years of 
follow-up, local control was identical (93%) in both arms of the study, but a small 
advantage in overall survival in favor of preoperative radiotherapy was statistically 
significant [53]. This has not been substantiated with 5-year results. The 5-year 
results for preoperative versus postoperative treatment, respectively, were as follows: 
local control, 93% versus 92%; metastatic-relapse free, 67% versus 69%; recurrence-
free survival, 58% versus 59%; overall survival, 73% versus 67% (P = .48), cause-
specific survival, 78% versus 73% (P = .64). Only resected margins were significant 
for local control. Tumor size and grade were the only significant factors for 
metastatic-relapse, overall survival, and cause-specific survival. Grade was the only 
consistent predictor of recurrence-free survival. 
 
 Rationale for Postoperative External-Beam Radiation Therapy: It is 
rational and convenient to sterilize microscopic nests of residual disease without 
postponing surgery. Its use is supported by numerous single-institution studies, and it 
has been shown to enhance local control in a randomized trial that compared 
conservative surgery and radiotherapy to conservative surgery alone [51]. Canadian 
Sarcoma Group randomized trial demonstrated that preoperative radiotherapy 
doubles the risk of early acute wound complication compare to post operative 
radiotherapy (29%vs 14%). This observation seems to apply almost exclusively to 
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lower limb lesions [52]. The significant limitations of postoperative EBRT are 
related to the less precise target volumes compared to those of preoperative EBRT.  
Postoperative volumes are larger and associated with higher doses, both of which 
increase the late tissue morbidity. Late morbidity in the same trial includes increased 
tissue fibrosis and edema mediated by larger doses and larger irradiated volumes in 
the postoperative setting. Late bone fracture may be related in part to higher 
radiotherapy doses and larger volumes associated with the timing of radiotherapy. 
 
 Relative advantages and disadvantages exist to the use of preoperative and 
postoperative EBRT (Table-1).  
 
Table-2: Advantages and disadvantages of Pre-operative and Post-operative 
radiotherapy in soft tissue sarcoma 
Pre-operative radiotherapy 
Advantages 
• Permits radiation  volumes and better tissue sparing possible 
• Total dose lower than with adjuvant radiotherapy 
• Reduces tumor dissemination during surgery 
• Better blood supply: possibly lower dose needed to control disease 
• Requires preoperative multidisciplinary assessment (major benefit) 
• Potential to reduce micrometastasis, may confer survival advantage 
Disadvantages 
• Complications and side effects are increased 
 23
• Overall survival is not improved 
• Interpretation of histology can be more difficult after surgery 
Post-operative  radiotherapy 
Advantages 
• Wound complications are less  
• Less requirement for preoperative multidisciplinary assessment 
• Final margins available to help determine need for radiotherapy 
• No delay in surgery because of complications from radiotherapy 
Disadvantages 
• Requires treatment of larger volumes 
• Increased late tissue morbidity (dose and volume related) 
• Does not improve overall survival 
 
 Dose and volume of radiation: The dose of radiotherapy represents an 
additional unexplored area. Postoperative radiotherapy volumes are significantly 
larger because they encompass all surgically manipulated tissues and because 
anatomic planes are disrupted and no longer provide containment barriers to tumor 
growth and must be considered high risk. Subsequently, the volume is reduced to the 
immediate area of origin of the tumor, with recognition that this is impossible in 
some anatomic sites due to the proximity of critical anatomy. These guidelines 
follow those of the American Brachytherapy Society of at least 2- to 5-cm 
longitudinal margin beyond the CTV and at least 1 cm beyond the lateral edge of the 
CTV.  
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 The preoperative dose used in most institutions is approximately 50 Gy in 
daily fractions of 1.8 to 2.0 Gy over approximately 5 weeks. A postoperative boost is 
administered only if the surgical margins are positive, although it is unclear whether 
this is beneficial. Stoeckle et al. described that there is no benefit in giving post 
operative boost to tumor bed in margin positive [54]. Quality of life and limb 
function, however, depend on achieving a good local control and on radiation dose 
and technique. Radiotherapy also is appropriate in resected STS with positive 
margins. In such cases better local control is obtained with doses higher than 64 Gy 
and in superficial locations on the extremities [55]. 
 
Brachytherapy (BRT):  
 
 Brachytherapy is an attractive approach because patients usually leave the 
hospital having completed all their treatment in about 2 weeks compared to a 6- to 7-
week course of EBRT [56]. Radiation will be delivered through the catheters which 
are place during the time off surgery usually after sixth postoperative day to allow 
enough time for wound healing. Unlike in postoperative external beam radiation, no 
attempts are made to treat large margins or to include the scar and the drainage site, 
although it is acknowledged that this approach has not been formally compared with 
EBRT in similar cases. The rapid dose fall-off with BRT usually spares more normal 
tissue than EBRT, except when precision techniques such as IMRT are used. In 
patients treated with BRT alone, the dose is usually 45 Gy given over 4 to 6 days, 
and when given as a boost, the dose is usually 15 to 20 Gy plus 45 to 50 Gy with 
EBRT. The most commonly used isotope is low-dose-rate iridium-192; however, 
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high-activity iodine-125 is occasionally used in young patients or to protect the 
gonads. High-dose-rate iridium-192 has been advocated to take advantage of its 
radiation safety and dose-optimization capabilities. 
 
 Adjuvant BRT was evaluated in a randomized trial to determine its role after 
complete gross resection. The 10-year actuarial local control rates were 81% and 
67% (P = 0.03) in the BRT and no-BRT groups, respectively [50]. This improvement 
in local control, however, was limited to patients with histologically high-grade 
tumors with local control of 89% and 64% (P = .001) in the BRT and no-BRT 
groups, respectively. No benefit in low grade tumor. At MSKCC, EBRT is added to 
BRT only when the geometry of the implant is suboptimal or there is a positive 
surgical margin. The American Brachytherapy Society has also recommended that 
BRT should not be used as a sole treatment modality in several situations like:  
 
1. If the CTV cannot be adequately encompassed in the implant geometry. 
2. When the proximity of critical anatomy is anticipated to prevent 
administration of a meaningful dose. 
3. When the resection margins are positive, and  
4. If there is skin involvement. 
 
 In such situations use of external-beam radiotherapy alone or with BRT may 
be used. One of the most attractive aspects of BRT is the ability to deliver further 
radiation in previously irradiated patients who may otherwise need amputation to 
obtain good local control. The Brachytherapy CTV may be difficult to define, but in 
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general it is represented by the volume of tissue considered at risk for microscopic 
extension of tumor and includes the tumor bed visualized on radiographic studies and 
under direct inspection intraoperatively. The dose of radiotherapy represents an 
additional unexplored area.  
 
Adjuvant Chemotherapy: 
 
 STS always have been considered to be less chemosensitive. Approximately 
50% of patients develop distant metastasis even with adequate local control of 
disease, usually to the lungs (extremity sarcomas) or liver (abdominal primary), it 
was expected that adjuvant chemotherapy would help to decrease the frequency of 
distant metastasis and increase overall survival. Many randomized trials have used 
anthracyclines, adriamycin alone (epirubicin, which is less cardiotoxic) or in 
combination with others like ifosfamide, cyclophosphamide, dacarbazine, 
actinomycin, methotrexate, and cisplatin. The small size of most other adjuvant 
chemotherapy trials makes interpretation on an individual basis difficult because 
most studies had no statistical power to detect small changes in overall survival. 
Hence role of adjuvant chemotherapy was analyzed in the STS Meta-Analysis 
Collaboration’s of 14 trials of chemotherapeutic regimens using doxorubicin and was 
found to improve the local recurrence–free interval (6%), the distant relapse–free 
interval (10%) and recurrence-free survival (10%) from 45% to 55% at 10 years, but 
its effect on overall survival was only a trend. There was a higher benefit for tumors 
localized to the extremities, with a significant increase in survival rate (7%) [57]. 
After this meta-analysis, three more randomized studies using combinations 
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adriamycin and ifosfamide were undertaken to clarify the still-controversial results 
concerning adjuvant chemotherapy. These studies, with a wide interstudy variability, 
failed to demonstrate an improvement in survival [58-60]. 
 
Preoperative chemotherapy 
 
 Beginning in the 1970s in the United States and the 1980s in Europe, studies 
have been conducted to evaluate the advantages of preoperative (or neoadjuvant) 
chemotherapy, which in theory would lead to the rapid and measurable volumetric 
reduction of primary tumor, would measure in vivo chemosensitivity to the 
prescribed drugs, and would act immediately on possible occult micrometastases. 
The studies are few, and the number of patients in the studies is low. Nevertheless, 
the results seem to demonstrate the same advantages observed with postoperative 
chemotherapy. As Pisters [61] noted, ‘‘ it is important to bear in mind that one of 
every two patients will live at least 5 years without pre- or postoperative 
chemotherapy.’’ The retrospective analyses of the role of chemotherapy for stage III 
sarcomas from the experience gained at the MSKCC and at the MD Anderson 
Cancer Center (Houston, Texas) have yielded interesting results [62,63]. The clinical 
benefits associated with doxorubicin-based chemotherapy seem not to be sustained 
beyond 1 year, suggesting caution in the interpretation of adjuvant chemotherapy 
trial. The MSKCC investigators retrospectively compared the treatment of primary 
high-grade sarcomas with neoadjuvant chemotherapy (doxorubicin, ifosfamide, and 
Mesna) or with surgery alone. There was a significant improvement in disease-
specific survival in patients who had sarcomas larger than 10 cm in the group treated 
with chemotherapy [63]. 
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Chemoradiation 
 
 A possible synergistic effect of combined radiation and chemotherapy has 
been tried. Combined therapy has been investigated continually for almost 20 years, 
and studies have confirmed the drastic reduction in the number of amputations, the 
reduction of recurrences, and the possibility of achieving complete response. High-
risk soft tissue sarcomas (i.e., those of large size, deep location, and high tumor 
grade) present a significant dual threat locally and at distant anatomic sites. In 
Massachusetts General Hospital, interdigitating courses of chemotherapy and a lower 
total dose of radiotherapy were used: three courses of doxorubicin, ifosfamide, 
mesna, and dacarbazine and two 22-Gy courses of radiation (11 fractions each) for a 
total preoperative radiation dose of 44 Gy. An additional 16-Gy boost dose (in eight 
fractions) was delivered for microscopically positive surgical margins [64]. The 5-
year actuarial local control, distant metastasis-free survival, and overall survival rates 
for the chemoradiation group were 92%, 75%, and 87%, respectively. Local and 
systemic toxicity included significant and expected wound-healing complications in 
the lower limbs evident in 29% [65]. A multicenter study that included 64 patients 
analyzed using the same protocol has shown significant toxicity, with 3 patients (5%) 
having experienced fatal grade 5 toxicities consisting of myelodysplasia in 2 and 
sepsis in 1. Moreover, another 53 patients (83%) experienced a variety of grade 4 
toxicities, and 5 patients required amputation [66]. Concurrent chemoradiation can 
be used in highly selected patients with caution. 
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Intra arterial chemotherapy   
 
 Concept of this technique to improve local control and convert borderline 
operable tumor where radical procedures culminant into limb loss. Intra-arterial 
chemotherapy has the potential benefit of providing higher doses of chemotherapy to 
the affected limb as first pass. Single agent adriamycin/cisplatine or in comination 
chemotherapy have been used in many studies in conjunction with radiation and 
surgery. Intra-arterial chemotherapy has been used in conjunction with radiation. In a 
neoadjuvant study at UCLA, patients received 3 days of intra-arterial doxorubicin 
before administration of 35-Gy external-beam radiation over 10 days or 17.5 Gy 
administered over 5 days [67]. Patients were then randomly assigned to receive 
postoperative doxorubicin intravenously or no further chemotherapy. No difference 
in survival or local control was noted in this study. Thereafter, a randomized trial by 
the same group examined preoperative intravenous versus intra-arterial 
chemotherapy before radiation (28 Gy given over 8 days) followed by wide excision. 
There was no difference in local recurrence or survival between the 45 patients 
receiving intra-arterial doxorubicin and the 54 patients receiving intravenous 
doxorubicin Limb salvage conversion was marginal with high rate of complications 
in intra-arterial chemotherapy. There was no difference in local recurrence or 
survival between the patients receiving intra-arterial doxorubicin and the patients 
receiving intravenous doxorubicin in randomized trial [68]. The complication were 
high both types including thromboembolism, infection, gangrene, and problems with 
wound healing, requiring amputation. Pathologic fractures have been reported in 
patients receiving chemotherapy and relatively larger doses of radiation. At present 
intra-arterial chemotherapy has a limited role in the treatment of extremity sarcomas. 
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Hyperthermia and limb perfusion  
 
 Limb perfusion in STS of the extremities is a practice dating back to the 
1970s .Here limb perfusion requires isolation of the arterial and venous system of the 
limb by means of a tourniquet and obtaining access to arteries and veins supplying 
the limb. The arterial and venous supplies of the limb are connected to an 
extracorporeal circulation system to isolate the limb from the rest of the body. 
Recirculation of the blood from the limb is performed by a heart-lung machine to 
reoxygenate the blood. Care is taken after isolation of the limb to ensure that there is 
no leakage of the circuit into the systemic circulation; technetium-labeled albumin is 
injected into the circuit, and a probe is used over the heart to ensure isolation of the 
bypass circuit. Because mild hyperthermia makes chemotherapy more effective 
hence the blood of the circuit is often warmed to 39°C to 40°C [69]. A number of 
chemotherapeutic agents have been used for limb perfusion, such as melphalan, 
nitrogen mustard, dactinomycin, and doxorubicin. The most effective agent has been 
melphalan when given with tumor necrosis factor (TNF). After isolation of the 
extremity, melphalan (10 to 13 mg/L limb volume) was perfused into the limb with a 
dose of TNF ten times the lethal dose for humans, under mild hyperthermic 
conditions [69]. In early studies interferon- α was included in the regimen, but it was 
later dropped because it did not appear to improve results over melphalan and TNF 
alone. Both components of the regimen appeared important; the omission of TNF led 
to a decrease in tissue dose of melphalan, probably from its effects on the tumor 
vasculature. Surgery to remove residual tumor was performed 2 to 4 months after 
limb perfusion. With a median follow-up of 3 years, 71% of patients had successful 
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limb salvage, 71% of patients had successful limb salvage following isolated limb 
perfusion. It is difficult to compare this approach to standard chemotherapy, given 
the heterogeneity of patients in the two types of studies. In aggregate, the response 
rate does appear to be higher in the perfusion studies than in the infusion studies. 
However, isolated limb perfusion requires substantial expertise and specialized 
dedicated equipment. Complications of this technique are high including shock (from 
systemic leak of TNF); infection; chronic damage to skin, muscles, and nerve; 
persistent edema; and arterial or venous thrombosis.  
 
 Hyperthermia has been used in other ways to enhance the effects of 
chemotherapy in patients with locally advanced disease. Whole-body hyperthermia 
using extracorporeal heating of blood has been combined with ifosfamide and 
carboplatin intravenous chemotherapy. Regional hyperthermia has demonstrated 
partial and complete responses in patients with locally advanced and metastatic soft 
tissue sarcoma. Regional hyperthermia provided through an external electromagnetic 
field (phased array) has been examined in combination with ifosfamide and 
etoposide, as well as other combinations of chemotherapy. Studies have 
demonstrated partial and complete responses in patients with locally advanced and 
metastatic soft tissue sarcoma. The hyperthermia used in these protocols is more 
aggressive than that used with limb perfusion; higher temperatures have led to a 
higher rate of local complications. Doxorubicin, ifosfamide, and etoposide 
chemotherapy with or without regional hyperthermia has shown superior local 
progression-free survival and disease-free survival on the hyperthermia arm with out 
over all survival benefit [70]. 
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Prognostic Factors 
 
 An analysis of prospective data collected from 1,041 patients older than 16 
years with localized soft tissue sarcoma of the extremity with long-term follow-up 
determined the clinical and pathologic factors that influence local recurrence, distant 
recurrence, and disease-specific and overall survival [44]. The 5-year survival rate 
was 76%, with a median follow-up of 4 years. Factors that increased the risk of 
recurrence are shown in table-3 [71].  Recurrent tumors, positive margins, in elderly 
patients, with histology of fibrosarcoma and MPNST were associated with high 
chance of local recurrence. Histologic subtype of liposarcoma was favorable for 
decreased distant recurrence rate when compared with other histologic types. Factors 
that increased distant recurrence rates were tumor size larger than 5 cm, high 
histological grade, deep location, recurrent disease at the time of presentation, and 
histologic subtype of leiomyosarcoma. 
 
Table-3: Relative Risk Influence on Recurrence of Localized Extremity Soft 
Tissue Sarcoma 
Variables 
Local 
Recurrence 
(P) 
Distant 
Recurrence 
(P) 
Disease-Free 
Survival (P) 
Age 1.6 (.001) - - 
Recurrent presentation 2.0 (.001) 1.5 (.02) 1.5 (.033) 
Fibrosarcoma 2.5 (.006) - - 
Malignant peripheral nerve tumor 1.8 (.001) - 1.9 (.008) 
Size >5 cm - 1.9 (.0001) 2.1 (.0001) 
Margin positive 1.8 (.0001) - 1.7 (.011) 
Depth - 2.5 (.0007) 2.8 (.0002) 
High grade - 4.3 (.0001) 4.0 (.0001) 
Leiomyosarcoma - 1.7 (.024) 1.9 (.012) 
 
French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91:1914 
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 For disease-specific mortality, large tumor size, high histological grade, deep 
location, recurrent disease at presentation, positive histological margins at the time of 
resection of the primary, lower-extremity site, and the histological types of  
leiomyosarcoma and malignant peripheral nerve tumor were all influential factors. 
Patients with a local recurrence of greater than 5 cm in less than 16 months had a 4-
year disease-specific survival of 18%, compared to 81% for patients with a local 
recurrence of 5 cm or less in more than 16 months [72]. Grade is a dominant factor in 
early metastasis most of them occur within 24 months, but in late recurrence initial 
size becomes equally important. 
 
Management of distant metastasis: 
 
 Approximately 20% of patients with a soft tissue sarcoma of an extremity 
develop pulmonary metastases, and in the majority, the lung remains the only 
clinically evident site of metastasis. Most metastases are detected in follow-up, 
although 80% develop within 2 years of diagnosis. Median survival from the time 
metastases are recognized is on the order of 8-12 months [73]. The most common 
tumors to develop metastases to the lung were, by order of frequency, 
leiomyosarcoma 21%, malignant fibrous histiocytoma 18%, synovial sarcoma 14%, 
and liposarcoma 12%. Although metastasis from soft tissue sarcoma, like those from 
osteogenic sarcoma, is usually confined to the lung, the results of resection are less 
favorable. In general these tumors are less sensitive to chemotherapy than 
osteosarcoma, which renders metastasectomy even more compelling. No data have 
suggested that neoadjuvant therapy improves resectability or survival. Hence, 
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patients who meet standard criteria for resectability should undergo metastasectomy. 
Metachronous metastasis prognosis depends on disease free survival, number 
metastasis, histology, grade and complete resection of metastasis.  A meta-analysis 
of 255 patients by the European Organization for Research and Treatment of Cancer 
(EORTC) Soft Tissue and Sarcoma Group reported 3-year and 5-year overall 
postmetastasectomy survival rates of 54% and 38% respectively, suggesting that 
such treatment can be considered if complete resection of the metastasis is possible 
[74]. Similar results was found later at the Memorial Sloan-Kettering Cancer Center, 
complete resection, disease-free interval greater than 12 months, and low-grade 
histology were significant favorable prognostic factors, whereas an age older than 50 
years and a diagnosis of liposarcoma or malignant peripheral nerve tumor were 
unfavorable prognostic factors. Of 213 patients undergoing metastasectomy, 161 
patients had a complete resection and achieved a 3-year survival of 46% and a 5-year 
survival of 37%. [75]. These results were significantly better than for patients who 
had an incomplete resection or who did not undergo surgery. 
 
 Recurrence in the lung develops in approximately half of the patients who 
have complete pulmonary resection of soft tissue sarcoma metastases. Median 
disease-free interval between metastasectomy and lung recurrence is 4 to 6 months. 
Experience with repeated thoracotomies is limited, with only a few reports in the 
literature. The National Cancer Institute and M. D. Anderson Cancer Center reported 
their experiences with 43 and 39 patients, respectively, and found a median survival 
of 25 and 28 months, respectively, after the second thoracotomy if complete 
resection is achieved. Complete resection, a single lung metastasis, and a disease-free 
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interval greater than 18 months were associated with improved survival when 
compared to patients with incomplete resection or without surgical options. In a 
series of 86 patients undergoing lung re-resection for metastatic soft tissue sarcoma, 
Weiser et al found an estimated 5-year survival of 36%. Poor prognostic indicators 
included more than three pulmonary nodules, nodules greater than 2 cm, and high-
grade histopathology of the primary tumor. 
 
 The next step was to assess when chemotherapy could be effective in patients 
undergoing metastasectomy. A European retrospective study at the Department of 
Surgery, Istituto Portugues de Oncologia Francisco Gentil (Lisbon, Portugal) 
analyzed prognostic factors in 85 patients who had undergone resection of 
pulmonary metastasis. In a multivariate analysis, only metastasis dimension and 
involvement of surgical margins were found to be independent factors associated 
with survival. Adjuvant chemotherapy was associated with survival only at 
univariate analysis [76]. A study conducted at the MSKCC of the effects of 
perioperative chemotherapy in patients undergoing pulmonary resection for 
metastatic STS of the extremities suggests that systemic chemotherapy has minimal, 
if any, long-term impact on outcome for these patients [78].  
 
Complications of Primary Treatment 
Wound Complications: 
 
 Both radiation and chemotherapy decreases the wound healing capacity. They 
suggested that radiation or antineoplastic drugs delivered more than 7 days before or 
 36
after the surgery were accompanied by minimal inhibition of wound healing [79]. 
The incidence of surgical wound complications was no different for patients 
undergoing preoperative chemotherapy than for patients undergoing surgery alone 
[79, 80]. There is definite increase in wound complication rates with radiation alone 
or in combination with chemotherapy. 
 
 Postoperative radiations volumes are larger and associated with higher doses, 
hence the late tissue morbidity are high. The late effects are increased tissue fibrosis 
and edema. Late bone fractures due to osteoporosis are related in part to higher 
radiotherapy doses and larger volumes associated with the timing of radiotherapy. 
Stinson et al. reported on 145 patients with soft tissue sarcoma who underwent limb-
sparing surgery and postoperative radiation with or without chemotherapy and found 
a 6% fracture rate [81]. In preoperative radiotherapy the targeted volume is known 
hence radiation field can be planned to reduce the dose to normal tissue. The risks of 
acute wound complication are high compared to postoperative radiotherapy but late 
toxicity is less. The risk of wound complication appears to be almost entirely 
confined to lower-extremity lesions in randomized trials [52,82] 
 
 In the MSKCC study wound complications were high in the randomized BRT 
trial [84]. The overall complication rate was 24% in the BRT arm, compared to 15% 
in the control arm (P = .18). The rate of reoperation was higher in the BRT group, 
9% versus 1% (P = .03).  In the Canadian trial comparing preoperative and 
postoperative irradiation, the wound complication were higher in preoperative 
radiation arm (35% vs. 17%; P = .01) [52]. The manner in which the wound was 
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closed, comorbidity, age, smoking history, and treatment center had no apparent 
influence on the risk.  
 
Other Complications 
 
 The development of bony fracture has been reported but the data are scant. 
The rate of fracture varies from 4% to 10% in radiation arm compared to 0% in the 
surgery alone arm [83,86]. Some authors suggested that prophylactic intramedullary 
fixation of the femur should be considered for patients undergoing resection of large 
tumors in the anterior compartment of the thigh requiring extensive periosteal 
stripping and adjuvant radiation therapy. Lin et al. evaluated 205 patients with soft 
tissue sarcoma of the thigh to determine the factors contributing to pathologic 
fracture of the femur in patients treated with adjuvant radiation (115 patients were 
treated with BRT alone, EBRT was used in 59, and 31 received a combination of 
EBRT and BRT)[85]. The 5-year actuarial risk was 8.6%, which on univariate 
analysis correlated with periosteal stripping (P = .0001), location in the anterior 
compartment (P = .008), female gender (P = .01), the use of chemotherapy (P = .02), 
age of 50 years or older (P = .03), and the use of EBRT instead of BRT (P = .04). On 
multivariate analysis only periosteal stripping retained significance (P = 0.01). The 
data from Princess Margaret Hospital, where a long-term follow up of patients with 
combined EBRT and limb-salvage surgery (without adjuvant chemotherapy) showed 
a significantly higher rate of pathologic fractures with higher radiotherapy doses (60 
or 66 Gy; rate of 10%) than with lower doses (50 Gy; rate of 2%) and a higher rate of 
fracture when radiation therapy was given postoperatively than when it was given 
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preoperatively [86]. The other complication encountered with adjuvant radiation is 
peripheral nerve damage. Le Pechoux et al. reported a rate of 1.6% of peripheral 
nerve damage in 62 patients treated with postoperative radiation [78]. Wound 
complications necessitating reoperation were seen more in patients who received 
BRT. Patients treated with postoperative radiotherapy have deteriorating rates of 
fibrosis and peripheral edema compared to those receiving preoperative radiotherapy, 
and it is conceivable that their risk of fracture ultimately may be greater.  
 
Follow up 
 
 Standard guideline for surveillance helps in identification of recurrence that is 
potentially curable and limb function can still be salvaged. The majority (90%) of 
extremity local recurrences occur during the first 5 years after treatment, of which up 
to two-thirds are detected during the first 2 years [87]. In a retrospective review of 
surveillance for follow-up of patients with high-grade extremity sarcomas, Whooley 
and associates evaluated the efficacy and cost-effectiveness of chest radiographs, CT 
scans of chest, imaging of the affected extremity, and blood tests [88]. Follow-up 
evaluations were performed every 3 months during the first 2 years, every 4 to 6 
months during the third posttreatment year, every 6 months for years 4 to 5, and 
annually thereafter. Their review found that physical examination was the most 
common method of detection of local recurrence (97%), with only one recurrence 
detected solely by surveillance MR (3%). Pulmonary metastasis was identified in 
40% of patients, but only 37% of these patients with pulmonary had symptoms as a 
basis for detection. Asymptomatic patients had their pulmonary metastasis initially 
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detected with chest radiographs in 83% of cases. In the remainder of patients, 
pulmonary metastases were detected solely with CT scanning. 
 
 NCCN guidelines [89] recommend that patient should be followed up as 
shown in table-4. Periodic imaging of primary site with MRI or CT scan should be 
considered if risks of recurrence are high, especially if the location or depth of the 
lesion makes physical examination unreliable for this determination. Ultrasound can 
be used in this setting as well. Local imaging may not be necessary after 5 years of 
treatment because the chance of local recurrence is smaller. 
 
TABLE -4: Surveillance guidelines for extremity soft tissue sarcomas (NCCN). 
Stage I Stage II and III 
• History & Physical examination 
every 3–6mo for 2–3y, then annually. 
• Consider imaging surgical site with 
scan annually based on estimated risk 
of locoregional recurrence. 
• Consider baseline imaging after 
primary therapy. 
• Consider chest X-ray every 6–12mo. 
• History & Physical examination 
every 3–4mo for 3y, then every 6mo 
for next 2y, then annually. 
• Imaging of primary site (MRI, CT, 
consider US). 
• Chest imaging (plain radiograph or 
chest CT) every 3–6mo for 5y, then 
annually 
 
 In our institute we follow up the patient every month in 1st year with clinical 
examination and chest X ray. Once in two months in 2nd year, once in 3 months in 3rd 
year and then every 6 monthly thereafter till 5 years. After five year annual follow up 
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chest X-ray and clinical examination, CT thorax was considered only if there was 
any abnormality in chest X-ray. In our institute metastectomy is considered only if 
disease free interval was there for more than 6 months with good performance status 
with few metastases.  No chemotherapy will be given following metastectomy. 
Patients who fail in lung or distant organ within 6 months after treatment or multiple 
bilateral metastases will be considered for best supportive therapy. 
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OBJECTIVES 
 
1. To analyze the patient characteristics, tumor characteristics and prognostic 
factors in patients with non metastatic soft tissue sarcoma of the extremities 
in adults.  
2. To study the role of re-excision for the previously unplanned excision. 
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MATERIALS AND METHODOLOGY 
 
 From January 1996 to December 2005, 145 consecutive cases of non-
metastatic adult soft tissue sarcomas of the extremities were included in the study. 
We excluded all pediatric sarcomas, Rhabdomyosarcoma, Ewing’s sarcomas and 
Primitive neuroectodermal tumors and stage IV disease at presentation or on 
evaluation. Others like Dermatofibrosarcoma protuberans and aggressive 
fibromatosis were also excluded.  
 
 Out of 145 patients 74 (51%) patients had undergone unplanned resection of 
a primary sarcoma at a nonspecialized center and were subsequently referred to our 
institution for further treatment. These were further categorized into re-excision and 
non re-excision   group depending on the review of operative notes, Pathology report, 
clinical and radiological findings.  a) Re-excision group contains 52(36%) patients, 
out of which 20 patients had clinical or radiological presence of residue disease and 
the remaining 32 patients had  only scar. b) Non re-excision group contains 22 
patients of which, 19 were considered for adjuvant radiation and 3 were kept under 
surveillance without re-excision.  
 
 All patients were thoroughly evaluated with detail history, physical 
examination, review of slides, paraffin blocks and surgical notes (if treated initially 
elsewhere). Metastatic workup includes chest X-ray and CT-scan of thorax. Extent of 
local disease was assessed by contrast CT-scan or MRI. 
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 Wide local excision with 2cm normal tissue margin all around is the main 
surgical resection technique. Radiotherapy was given if the size is more than 5 cm, 
high grade tumor and unplanned excision suspected to have contamination. External 
beam radiation was used in all such cases with doses ranging from 50 to 60 Gy with 
1.8 to 2 Gy fraction per day. In one patient brachytherapy was used. Chemotherapy 
was administered at the discretion of the multidisciplinary board. Anthracycline 
based chemotherapy was given only in young, high grade tumours. 
 
 As per our institute protocol lung metastectomy is considered only if disease 
free interval was there for more than 6 months with good performance status with 
few metastases.  No chemotherapy is given following metastectomy. Patients who 
failed in lung or distant organ within 6 months after treatment or multiple bilateral 
lung metastases will be considered for best supportive therapy. 
 
 Patients were followed up till august 2009. The recurrence pattern and the 
time for the tumor to recur were studied at follow up. Prognostic factors such as age 
group, grade, size, and histology, type of surgery and adjuvant treatment were 
studied that influence the survival. The prognostic effect of re-excision for the 
previous unplanned surgeries was studied. The analysis was done for entire 145 
patients and those had unplanned excision using the SPSS statistical package 
(version-10). 
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RESULTS 
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Results: 
 
 From January 1996 to December 2005, 145 consecutive adult patients 
diagnosed with non-metastatic extremity soft tissue were studied and followed up till 
August 2009. Mean duration of follow-up is 59months (2 - 142months). There were 
95 men and 50 women; their mean age was 40.7 years (median age 39years; range 16 
to 84).  
 
 The most common presenting symptom was painless swelling. The duration 
of symptoms varied from 1 to 240 months with mean duration of 30 months. Most 
common histology were Synovial sarcoma (23.4%), MFH (19.3%), 
Liposarcoma(7.6%), Pleomorphic sarcoma(8.3%) and not classified (spindle cell 
sarcoma- 21.3%). The characteristic of patients is shown in table-5. 
 
Table-5: Characteristics of patient, tumor and treatment 
Variables Number of patients (percentage) 
Age in yrs, median  
     Age < 40yrs 
     Age ≥ 40yrs 
Sex 
      Male 
      Female 
 
39 (15-84) 
74 (50.9%) 
71 (49.1%) 
 
95 (65.5%) 
50 (34.5%) 
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Size , median in cm  
       Unknown 
       T≤5cm 
       T>5cm 
Tumors > 10 cm 
Grade  
          Low grade 
          High grade 
Stage  
         Unknown  
         Stage I 
         Stage II 
         Stage III 
Amputation  
Positive margins  
Adjuvant treatment  
        No adjuvant  
        Radiation only 
        Chemotherapy± radiation  
8 (3-44) 
21 (14.5%) 
35 (24.1%) 
89 (61.4%) 
36 (24.8%) 
 
24 (16.5%) 
121(83.5%) 
 
21 (14.5%) 
22 (15.2%) 
26 (17.9%) 
75(51.7%) 
53 (36.5%) 
4 (2.7%) 
 
67 (46.2%) 
54 (37.2%) 
24 (16.6%) 
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 Surgical resection was done with 2cm margin all around except when tumor 
is close to the nerves, vessels and bone where perineurium, periostium and sheath 
covering vessels were taken as margin.  
 
 Surgery is the main treatment. Limb salvage surgery was done in 92 patients 
(64 %).  Fifty three patients (36%) had major amputation. Adjuvant radiation was 
given in 54 patients, chemotherapy and radiation in 12 and chemotherapy   alone in 
12 and 67 did not receive any adjuvant treatment. Five patients treated with neo-
adjuvant therapy, 2-radiation, 2- chemotherapy and 1-chemoradiation. Out of these 2 
were salvaged and 3 underwent amputation. 
 
 Recurrence:  Totally 47(32.4%) patients had recurrence including local 
recurrence in 13 cases(9%) , local recurrence with regional node metastases in 
3(2%), failed only in regional lymph nodes in 4(2.7%), with both local and distant 
metastasis in 2(1.3%) and remaining 25(17.3%) failed in distant site alone as shown 
in table-13.  
 
 Median time for distant metastasis was 4 month (1- 44) and 90% had 
recurrence in lung. Lymph node metastasis in our study was 4.8% seen in synovial 
sarcoma, pleomorphic sarcoma, leiomyosarcoma, MFH and unclassified spindle cell 
sarcoma. 
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Table- 6: Number of recurrence and effect of grade, size and radiation on 
recurrence. 
Factors Local 
recurrence 
Regional 
recurrence 
distant 
metastasis 
Total Number of recurrence 
47(32.4%) 
13(9%) 
 
7(4.7%) 27(18.6%) 
Grade  
       Low (24) 
       High (121) 
 
2 (8.3%) 
11 (9.0%) 
 
Nil  
7 (5.8%) 
 
Nil 
27 (22.3%) 
Size  
        Tx (21) 
       ≤ 5cm (35) 
       >5cm (89) 
 
3 (14.2%) 
4(11.4%) 
6 (6.7%) 
 
2 (9.5%) 
1 (2.8%) 
4 (4.5%) 
 
2 (9.5%) 
7 (20%) 
18 (20.3%) 
(Excluding amputation) 
           Without RT (24) 
           With RT (54) 
 
3(12.5%) 
6(11.1%) 
 
Nil  
2 (3.7%) 
 
1(4.15%) 
7(13%) 
 
 Recurrence was treated according to site, extent, number, disease free interval 
and ECOG performance status. 12 patients with local recurrence were salvaged with 
wide local excision and one patient received palliative radiation only. One patient 
with lymph node metastasis underwent nodal clearance and lung metastectomy was 
done in 4 cases. Twenty five were sent on supportive care and 2 defaulted for 
treatment. 
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 Reconstruction: Primary closure of wound was possible in 127 patients, 
remaining 18 need reconstruction like local advancement flap in 5, gastrocnemius 
flap + split skin graft in 2, gracilis muscle flap in 1, posterior interosseous flap, 
pectoralis major muscle flap, tensor fascia lata flap, anterolateral thigh flap in one 
each cases and split skin grafting in six.  
 
 Complication: Postoperative complication was noted in 11 % (16/145) cases. 
Two major complications were flap failure requiring reconstruction with free flap. 
Others like wound infection in 4, wound gaping in 3, marginal necrosis in 3, 
hematoma, abscess and skin graft loss in one cases each was seen. 
 
 The principal host, tumor-related and treatment prognostic factors that predict 
for overall survival were assessed include sex, age group, histological grade, tumor 
size, and adjuvant treatment were analyzed for 145 patients as shown in the table-7. 
  
The five year disease free and overall survival for 145 Patients is 60.1% and 
69.2% respectively is shown in graphs. 
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Overall survival and disease free survival graphs for 145 patients with non-
metastatic extremity soft tissue sarcomas. 
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Table -7: univariate analysis for entire 145 patients: 
 
Variables Number of patients 
(%) 
Overall survival 
(%) 
p-value 
Age group 
       < 40 yrs 
       ≥40 yrs 
Sex 
       Male 
       Female 
Size  
       Tx 
       T1 
       T2 
Grade 
       Low 
       High  
 
Adjuvant treatment 
(excluding amputation) 
    Without Radiation  
       With Radiation      
 
74 (50.9%) 
71 (49.1%) 
 
95 (65.5%) 
50 (34.5%) 
 
21 (14.5%) 
35 (24.1%) 
89 (61.4%) 
 
24 (16.5%) 
121(83.5%) 
 
 
 
24 (16.5%) 
54 (37.2%) 
 
80.04 
57.53 
 
66.53 
73..08 
 
83.95 
81.30 
60.47 
 
95.65 
63.70 
 
 
 
63.77 
78.78 
 
0.0183 
 
 
0.940 
 
 
 
0.012 
 
 
0.0037 
 
 
 
 
0.446 
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 High grade tumors, size more than 5cm and in patients aged more 40 yrs had 
significantly lower survival. Chemotherapy (p-0.428) and histological type (p-0.606) 
did not affect the survival. Margin positivity (0.464) did not effect the survival 
expect increased risk of local recurrence (50% recurred)  
 
Table-8: multivariate analysis. 
Variables  Number of patients  p-value 
Size 
 
Grade 
 
Age group  
 
≤5cm(35) 
>5cm (89) 
Low (24) 
High (121) 
< 40yrs (74) 
≥40yrs (71) 
0.076 
 
0.012 
 
0.010 
 
 
Analysis of unplanned excision: 
 
 Out of 74 patients who had unplanned excision elsewhere; 52 patients 
underwent re-excision here, 19 were considered for adjuvant radiation and 3 were 
kept under surveillance without re-excision (after reviewing surgical and 
pathological reports). The residual disease was found in 50% (26 /52). Of the 52 
patients, thirty two patients had only scar without any palpable lump and with normal 
imaging of which 37.5% (12/32) had microscopic residual disease. Disparity 
between the clinical and pathological residual disease is shown in table-9: 
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Table -9: clinical and pathological residual correlation in re-excision group 
 
Total 52 patients Pathological residue 
present % (no of 
patients) 
Pathological residue 
absent 
% (no of patients) 
Clinically or radiologically 
residue present (20) 
70% (14) 
 
30% (6) 
Clinically or radiologically 
residue absent (32) 
37.5% (12) 62.5% (20) 
 
Table-10: Recurrence pattern between two groups: 
 
Group Number of patients Local Regional Distant 
Re-excision done 
No re-excision 
52 
22 
1(1.9%) 
8(36.4%) 
1(1.9%) 
1(4.5%) 
8(15.4%) 
2(9%) 
Total number 74 9 (12.2%) 2 (2.7%) 10(13.5%) 
 
 Local recurrences were high in those who did not undergo re-excision for 
unplanned excisions.  The 5-year disease free survival and overall survival is shown 
in table-11, the 5-year disease free survival for re-excision group was 77.8 % versus 
56.6% for those who did not undergo re-excision (p-0.014), which is statistically 
significant.  In re-excision group there is trend towards increase overall survival but 
it was not statically significant (0.464). 
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Table-11: disease free survival and overall survival 
 
Variables(No of 
patients) 
Disease free 
survival (%) 
p-value Overall 
survival (%) 
p-value 
 
Re-excision 
done(52) 
77.88  
0.0148 
83.75  
0.464 
No re-excision 
(22)  
56.63 79.91 
 
Table-12: 5yr disease free survival in unplanned excision group. 
 
Variables Re-excision done 
(%) 
No Re-excision 
(%) 
p-value 
Size 
      ≤5cm 
      >5cm 
Grade  
      Low  
      High  
 
78.54 
73.20 
 
100.00 
73.20 
 
71.43 
62.50 
 
100.00 
51.92 
 
0.317 
0.504 
 
0.312 
0.030 
 
 In low grade tumors re-excision did not affect the local recurrence or survival 
but in high grade tumors re-excision has shown significant disease free survival. In 
re-excision group there is trend towards increasing survival in tumors more than 5cm 
but it was not statically significant. 
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 Prognostic effect of residual disease: The prognostic effect of residual disease 
in the pathologic specimen was studied in the subset of patients who underwent re-
excision. Presence or absence of residual disease following re-excision did not have 
an impact on disease free survival or over all survival.   
 
Table-13: significance of residual tumor on survival 
 
Re-excision 
 
Number of 
cases 
5yr disease free 
survival 
5yr overall 
survival 
p-
value 
Pathological residue  
Present  
Absent  
 
50% (26/52) 
50% (26/52) 
 
 
75.17% 
81.17% 
 
77.75% 
89.86% 
 
0.1477 
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DISCUSSION 
 
 Soft tissue sarcomas (STS) are rare tumors; the crude incidence for male is 1 
per lakh and 0.9 per lakh for female according to Madras Metropolitan tumor registry 
[90]. According to our hospital based registry, soft tissue tumors accounts 2% of 
male and 1 % of female cases for total number of new cases registered approximately 
9000 to 12000 annually [91]. Approximately 30% have metastatic disease at 
presentation. The world wide incidence is 1 to 2 cases per 100,000 per year [1, 2]. 
 
 Synovial sarcoma is the most common histology in our study compared to 
others series, where MFH is being common [29, 32, 35]. Histological subgroup did 
not show any survival difference, probably due to small number in each group with 
varying degree of grade and size. 
 
 In our study, limb salvage surgery was possible in 64 percent of patients 
while 36% of the patients underwent amputation. This is probably due to delay in 
presentation and large size at diagnosis. In our study 61 % of patients had tumors 
more than 5cm and 24 % had more than 10 cm.  
 
 In the our study, we found that sarcomas larger than 10 cm in size carried a 
2.5 -fold greater probability of death compared with sarcomas that were less than 5 
cm in size (p = 0.017).  
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 The benefits of adjuvant radiation therapy after surgery for soft tissue 
sarcomas of the extremities have been shown in randomized clinical trials comparing 
conservative resection alone with resection followed by adjuvant radiation therapy 
[51, 52, and 53]. In our study, a patient who received adjuvant radiation there was a 
trend towards increased survival but it was not statistically significant. In Sarcoma 
Meta-analysis Collaboration, adjuvant chemotherapy has showed significant survival 
benefit of 7% in extremity soft tissue sarcomas. In our study out of 121 high grade 
soft tissue sarcomas, only 24 patients received adjuvant chemotherapy. There was no 
statistically significant survival benefit for adjuvant chemotherapy. This may be 
because of selection bias and small sample size receiving adjuvant chemotherapy.  
 
 In our series, univariate analysis for low grade, size less than 5cm and age 
less than 40years were identified as important prognostic factors. In multivariate 
analysis, statistically significant survival advantage was found for grade of tumors 
and age less than 40 years. Size, gender, histopathological subtypes and adjuvant 
therapy did not show any statistical significance.  
 
 Some series of extremity sarcomas have shown that grade, size, age, and 
Histologic subtype were important prognostic factors in predicting overall survival 
[92, 93, and 94]. In Berlin et al series the mean mitotic activity was an additional risk 
factor for local recurrence and survival [93]. 
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 Lymph node metastases were seen in 4.7% (7/145) of patients in our study in 
tumors like synovial sarcoma, pleomorphic sarcoma, leiomyosarcoma, MFH and 
unclassified spindle cell sarcoma. In other literature nodal metastasis varied from 3.4 
to 15% [96, 97] 
 
Unplanned excision:  
 
 Most of the soft tissue tumors are benign; the incidence being malignant is 1 
in 100 cases of benign tumors [5].  Probably this is the reason why STS are often 
thought to be benign and are excised without adequate margins in nonspecialist 
centers and without oncological expertise. These suspicious masses should be 
subjected to further investigation before definitive excision. In our study 70% had a 
treatment in nonspecialist centre.  
 
 The correlation between radiological findings and residual tumor is poor after 
unplanned resection due to the disruption of anatomical planes, and the role of 
magnetic resonance imaging in the assessment of residual tumors following 
unplanned resection is doubtful [30]. In our study 30% of patients did not have any 
pathological residue which was reported on imaging with CTscan or MRI. Manoso et 
al reported that 90% of patients with radiological evidence of tumor positivity had 
residual disease, whereas this rate was 25% for patients with no radiological 
evidence of tumor [31]. In our study among patients who underwent unplanned 
excision with post excision local imaging being normal, 37.5 % had microscopic 
residual disease on re-excision. 
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 The rate of re-excisions in our series is 37.2% which is similar to other 
published series shown in table-14.  Re-excision of unplanned surgeries was 
performed in 24% to 100% of patients in previous studies [29, 33, 35, 37-39]. 
Various studies have reported a residual tumor rate of 24% to 63% after unplanned 
resections [29, 32-39]. The residual disease rate in our series is 50%, which is almost 
similar to other series. 
 
Table-14: Rate of re-excision and residual disease in the re-excised specimen in 
major published series 
 
Study 
No. of 
patients 
Site Presentation Re-excision 
Residual 
disease 
Giuliano 1985 90 Ext Primary 90 (100%) 51% 
Lewis, 2000 
,MSKCC 
1092 Ext Primary 407(37%) 39% 
M. Fiore , 2006 597 Ext Primary 318 (53%) 24% 
Zornig,1995 189 Ext , 
trunk 
NS 67(35%) 45% 
Karakousis 
1999 
194 Ext Any 104(43%) 40% 
Zagars 2003 1225 Any Any 295(25%) 45% 
Present study 
Cancer institute 
(WIA) 2010 
145 Ext Primary 52(37.2%) 50% 
 60
 Ueda et al. [95] described that the local recurrence rate was higher in patients 
who received inadequate initial resection than in patients who received successful 
primary tumor resection in the same institution.  
 
 In our study, out of 74 unplanned excisions, 22 patients did not under go re-
excision, of which 19 had adjuvant radiotherapy. Despite being margins negative and 
receiving adjuvant radiotherapy, 36% (8/22) of these patients developed local 
recurrence. On contrary, recurrence rate was 1.9% (1/52) among the patients who 
had re-excision after an unplanned excision. This indicates re-excision should be 
considered in all cases undergoing unplanned excision. 
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CONCLUSIONS 
 
 A patient with any soft tissue swelling, which raises a suspicion of soft tissue 
sarcoma, should be referred to a specialist centre, where a multidisciplinary team 
with good experience will be available.  
 
 Surgery is the main treatment modality. Grade and age were found to be 
significant prognostic factors for survival. 
 
 All patients who have undergone unplanned excision for soft tissue sarcomas 
should be followed by wide re-excision because substantial number patients will 
have residual disease even with normal imaging and re-excision has shown a 
significant decrease in risk of local recurrence. 
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PROFORMA 
 
Name:    Age:   Sex:    
OP no:    CI no: 
Date of admission: 
Personal history: 
Smoking:  
Comorbid condition:  
Family history: 
Treated in other institution (unplanned excision):  Yes / No 
Diagnosis: 
Margins: 
Recurrent:  Yes / No    
Diagnosis: 
Primary: Yes /  No 
Presenting symptoms: 
Swelling: 
Pain: 
Ulcer: 
Neurological symptoms: 
Other: 
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Clinical features: 
Location: 
Size: 
Skin:  
Neurovascular status: 
Regional nodes: 
Imaging: 
Chest X-ray: 
CT Chest: 
Imaging local part 
CT scan 
MRI: 
Bone scan: 
Biopsy 
Trucut biopsy: 
Open biopsy: 
Repeat biopsy: 
Out side treated slide review: 
Final diagnosis: 
IHC: 
Treatment:  
Neoadjuvant treatment: 
Surgery: 
Date of surgery 
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Type of surgery 
 
Defect: 
Reconstruction: 
Morbidity: 
Date of discharge: 
Post operative histopathology: 
 
 
Margins: 
Re- excision for positive margins: 
 
Adjuvant treatment: 
Date of completion of treatment: 
Status at first follow up: 
Date of recurrence: 
Status at recurrence: symptomatic/ asymptomatic  
Type of recurrence: 
Treatment of recurrence: 
 
Date of last follow up: 
 
Status at present: 
